Advertisement
Advertisement
U.S. markets open in 5 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Atara Biotherapeutics, Inc. (AT2.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
4.7780+0.1110 (+2.38%)
As of 09:01AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.6670
Open4.7780
Bid4.7590 x N/A
Ask4.8870 x N/A
Day's Range4.4750 - 4.6670
52 Week Range2.6730 - 13.4950
Volume80
Avg. Volume30
Market Cap469.983M
Beta (5Y Monthly)0.77
PE Ratio (TTM)N/A
EPS (TTM)-3.4650
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AT2.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      THOUSAND OAKS, Calif., January 13, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired emp

    • Business Wire

      Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

      THOUSAND OAKS, Calif., January 04, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Fr

    • Motley Fool

      3 Under-the-Radar Biotech Stocks to Buy in 2022

      Beam Therapeutics is different from many CRISPR-editing biotechs in that it uses ex-vivo base cell editing instead of nuclease cell editing. Beam stock is down more than 48% so far this year, but the company has a growing pipeline that shows promise. Its lead therapy is BEAM-101 to treat various blood diseases, including sickle cell disease (SCD) and beta thalassemia.

    Advertisement
    Advertisement